Condition: Biliary Tract Cancer · Sponsor: West China Hospital
Advanced biliary tract cancer has a poor prognosis and limited efficacy with current regimens. This multicenter single-arm phase Ib/II trial explores the efficacy and safety of HAI-GP chemotherapy combined with intraoperative arterial envafolimab and lenvatinib as first-line therapy for unresectable BTC. It conducts dose exploration to confirm the optimal dosage and evaluates clinical outcomes, aiming to establish a better comprehensive treatment strategy.
This description comes directly from the study's public registry record.
Chang Liu, Doctor · 18980606382 · drliuchang@wchscu.cn
Ruihong Dai, Doctor · 18715779637 · 760173632@qq.com
Always discuss trial participation with your own doctor first.
| Study Chair Liu Chang , West China Hospital, Chengdu, Sichuan 610041 | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07636798